KPRX KIORA PHARMACEUTICALS INC

Overview and Growth

Fiscal 2025 results for KIORA PHARMACEUTICALS INC combined $0.00 of revenue with net loss of $10.84M and an operating cash outflow of $9.96M. The top line contracted 100.0% from $16.02M in fiscal 2024; this top-line contraction left the company with a smaller revenue base. Diluted earnings per share were -$2.64, translating the period’s attributable earnings into the amount reported for each diluted share. The per-share result recorded a 403.4% decrease from fiscal 2024 diluted EPS of $0.87. The diluted weighted-average share count was 4.10M, linking total earnings with the per-share result received by shareholders. Diluted shares moved 0.5% from 4.13M in fiscal 2024, leaving the current share base lower year over year. The company employed $24.25M of total assets, the balance-sheet base supporting its current operating and cash-flow results.

Profitability

The company recorded an operating loss of $12.83M after the reported operating expense base. After all below-operating-line items, the company recorded a net loss of $10.84M for the fiscal year. EBITDA was negative $12.81M, showing a deficit before interest, taxes, depreciation, and amortization. The company reported a pretax loss of $12.12M, before the effect of income taxes. An income-tax benefit of $1.28M improved the final result relative to pretax income or loss. Relative to period-end equity, the net loss represented 67.2%. The net loss equaled 44.7% of period-end assets, showing the deficit relative to the asset base. A $10.84M net loss replaced fiscal 2024 net income of $3.59M.

Liquidity and Capital Structure

At period end, the $24.25M asset base was financed through $8.13M of liabilities and $16.13M of equity. Current assets were $21.75M against $3.63M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. At 5.99x, the current ratio shows that short-term assets were greater than short-term liabilities at period end. Reported cash and equivalents were $8.70M, separating immediately recognizable cash resources from the rest of the current-asset base. The cash balance equaled 239.5% of current liabilities, showing how much near-term coverage came from cash alone. Book equity represented 66.5% of total assets, quantifying the balance-sheet share supported by shareholder capital. The liabilities-to-assets relationship was 33.5%, placing reported obligations against the full positive asset balance. Measured against total assets, cash and equivalents represented 35.9%, a balance-sheet composition measure rather than a liquidity forecast. Compared with $36.48M in fiscal 2024, the current asset base moved 33.5% and finished lower. Book equity was 37.4% lower than fiscal 2024 equity of $25.76M, showing how shareholder capital changed year over year. Compared with $3.79M in fiscal 2024, the current cash balance moved 129.3% and finished higher.

Cash Flow and Earnings Quality

Operating activities used $9.96M of cash, resulting in an operating cash outflow for the year. The company spent $110.79K on capital expenditures while operations also absorbed cash, so both ongoing activity and investment drew on liquidity during the period. The company recorded a $10.07M cash deficit after capital spending for the period. The free-cash-flow deficit equaled 41.5% of total assets, placing the cash shortfall against the company’s resource base. Operating cash flow moved from a $8.56M inflow in fiscal 2024 to a $9.96M outflow.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Oct 21, 2026.